IL154087A0 - Novel use of a peptide class of compound for treating non neuropathic inflammatory pain - Google Patents

Novel use of a peptide class of compound for treating non neuropathic inflammatory pain

Info

Publication number
IL154087A0
IL154087A0 IL15408702A IL15408702A IL154087A0 IL 154087 A0 IL154087 A0 IL 154087A0 IL 15408702 A IL15408702 A IL 15408702A IL 15408702 A IL15408702 A IL 15408702A IL 154087 A0 IL154087 A0 IL 154087A0
Authority
IL
Israel
Prior art keywords
pain
compound
inflammatory pain
inflammatory
novel use
Prior art date
Application number
IL15408702A
Other languages
English (en)
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL154087(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of IL154087A0 publication Critical patent/IL154087A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15408702A 2001-03-20 2002-03-19 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain IL154087A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01106891A EP1243262B1 (en) 2001-03-20 2001-03-20 Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
PCT/EP2002/003034 WO2002074784A2 (en) 2001-03-20 2002-03-19 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain

Publications (1)

Publication Number Publication Date
IL154087A0 true IL154087A0 (en) 2003-07-31

Family

ID=8176844

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15408702A IL154087A0 (en) 2001-03-20 2002-03-19 Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
IL154087A IL154087A (en) 2001-03-20 2003-01-22 Use of a compound or medicinal products that are acceptable for the preparation of a pharmaceutical compound for the treatment of sensitivity to sharpness or chronic pain

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154087A IL154087A (en) 2001-03-20 2003-01-22 Use of a compound or medicinal products that are acceptable for the preparation of a pharmaceutical compound for the treatment of sensitivity to sharpness or chronic pain

Country Status (30)

Country Link
US (3) US6803481B2 (enExample)
EP (2) EP1243262B1 (enExample)
JP (1) JP4955906B2 (enExample)
KR (1) KR100773100B1 (enExample)
CN (2) CN101332292B (enExample)
AT (2) ATE327744T1 (enExample)
AU (1) AU2002257681C1 (enExample)
BR (1) BR0205823A (enExample)
CA (1) CA2419397C (enExample)
CY (3) CY1105533T1 (enExample)
CZ (1) CZ20032763A3 (enExample)
DE (3) DE60120104T2 (enExample)
DK (2) DK1243262T3 (enExample)
EA (1) EA007532B1 (enExample)
ES (2) ES2262567T3 (enExample)
FR (1) FR09C0041I2 (enExample)
HU (1) HUP0303600A3 (enExample)
IL (2) IL154087A0 (enExample)
LU (1) LU91590I2 (enExample)
MX (1) MXPA03008467A (enExample)
NL (1) NL300399I1 (enExample)
NO (1) NO20033629D0 (enExample)
NZ (1) NZ523865A (enExample)
PL (1) PL216213B1 (enExample)
PT (2) PT1243262E (enExample)
SI (2) SI21170A (enExample)
SK (1) SK287539B6 (enExample)
UA (1) UA82645C2 (enExample)
WO (1) WO2002074784A2 (enExample)
ZA (1) ZA200300858B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435000T3 (es) * 2000-08-25 2013-12-18 Research Corporation Technologies, Inc. Aminoácidos anticonvulsionantes para el tratamiento del dolor
ATE327744T1 (de) * 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
BRPI0417101A (pt) * 2003-12-02 2007-02-06 Sanol Arznei Schwarz Gmbh uso de compostos de peptìdeo para tratamento de dor neuropática central
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
CN1950101B (zh) * 2004-04-16 2011-03-30 舒沃茨药物股份公司 肽化合物用于预防和治疗慢性头痛的用途
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
MX2007002269A (es) * 2004-08-27 2007-06-15 Sanol Arznei Schwarz Gmbh Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos.
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
AU2006208630B2 (en) 2005-01-28 2011-09-29 Ucb Pharma Gmbh SPM 927 for add-on therapy of schizophrenia
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
KR20090018863A (ko) * 2006-06-08 2009-02-23 쉬바르츠파르마에이지 통증성 의학적 상태를 위한 치료제 조합
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
KR20150003925A (ko) 2006-06-15 2015-01-09 유씨비 파르마 게엠베하 상승적 항경련 효과를 갖는 약제학적 조성물
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
CA2774569A1 (en) 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US20130251813A1 (en) 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide
GB2524689B (en) 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
ES2946109T3 (es) * 2012-05-10 2023-07-12 Solutex Na Llc Aceites con actividad antiinflamatoria que contienen mediadores pro-resolutivos especializados naturales y sus precursores

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (enExample) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5278729A (en) * 1992-04-10 1994-01-11 Magnavox Electronic Systems Company Compact rotatable electrical device
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
AU678884B2 (en) * 1994-01-22 1997-06-12 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
FI971412A7 (fi) 1994-10-05 1997-04-04 Darwin Discovery Ltd Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
JP4313435B2 (ja) 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
US6114390A (en) 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614542A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
ATE320249T1 (de) 1997-07-08 2006-04-15 Ono Pharmaceutical Co Aminosäurederivate
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU7696098A (en) * 1997-08-11 1999-03-01 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
ID24278A (id) 1997-10-31 2000-07-13 Basf Ag Turunan-turunan asam karboksilat baru dengan rantai sisi amida, pembuatan dan penggunaannya sebagai reseptor antagonis endotelin
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
CA2361402C (en) 1999-09-03 2009-05-12 Actelion Pharmaceuticals Ltd Bis-sulfonamides
SE0001373D0 (sv) * 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
SI1311256T1 (sl) * 2000-08-17 2005-12-31 Teva Pharma Uporaba derivatov amidov valprojske kisline in amidov 2-valproenske kisline za zdravljenje ali preprecevanje bolecin in/ali glavobolnih motenj
ES2435000T3 (es) 2000-08-25 2013-12-18 Research Corporation Technologies, Inc. Aminoácidos anticonvulsionantes para el tratamiento del dolor
WO2002042256A2 (en) 2000-11-21 2002-05-30 Ucb, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
ATE327744T1 (de) * 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
IL157093A0 (en) 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
MXPA03009689A (es) 2001-04-26 2004-02-12 Bristol Myers Squibb Co TABLETA FARMACEUTICA QUE TIENE ALTO CONTENIDO DE INGREDIENTE FARMACeUTICO ACTIVO (IFA).
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
DE60313634T2 (de) 2002-08-05 2008-01-31 Eli Lilly And Co., Indianapolis Piperazinsubstituierte arylbenzodiazepine
CA2505361A1 (en) 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
ES2300625T3 (es) 2002-11-18 2008-06-16 Bioprospecting Nb Inc. Peptido paralizante de musaraña para uso en terapia neuromuscular.
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
WO2004060352A1 (en) 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
US20040209960A1 (en) 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
US20040213842A1 (en) 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004100871A2 (en) 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EP1537862A1 (en) 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
BRPI0417101A (pt) 2003-12-02 2007-02-06 Sanol Arznei Schwarz Gmbh uso de compostos de peptìdeo para tratamento de dor neuropática central
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
CN1950101B (zh) 2004-04-16 2011-03-30 舒沃茨药物股份公司 肽化合物用于预防和治疗慢性头痛的用途
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
MX2007002269A (es) 2004-08-27 2007-06-15 Sanol Arznei Schwarz Gmbh Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos.
EP1642889A1 (en) 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP1688137A1 (en) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 for add-on therapy of schizophrenia
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain

Also Published As

Publication number Publication date
NL300399I1 (en) 2009-10-01
EP1243262B1 (en) 2006-05-31
AU2002257681B2 (en) 2007-06-07
SI21170A (sl) 2003-10-31
ATE327744T1 (de) 2006-06-15
PT1243262E (pt) 2006-10-31
PT1373300E (pt) 2009-07-22
CA2419397C (en) 2009-09-15
US20070054962A1 (en) 2007-03-08
HUP0303600A2 (hu) 2004-03-01
EP1373300B1 (en) 2009-05-20
US20050085423A1 (en) 2005-04-21
EA200300932A1 (ru) 2004-04-29
FR09C0041I2 (enExample) 2010-01-22
HK1058368A1 (en) 2004-05-14
DE60120104D1 (de) 2006-07-06
CY2009013I2 (el) 2012-01-25
EA007532B1 (ru) 2006-10-27
DE60232407D1 (de) 2009-07-02
DK1373300T3 (da) 2009-08-31
PL362985A1 (en) 2004-11-15
LU91590I2 (fr) 2009-10-05
PL216213B1 (pl) 2014-03-31
UA82645C2 (uk) 2008-05-12
IL154087A (en) 2010-05-17
US20030171300A1 (en) 2003-09-11
CA2419397A1 (en) 2002-09-26
WO2002074784A2 (en) 2002-09-26
CN1498103A (zh) 2004-05-19
DE60120104T2 (de) 2006-09-21
CN100415225C (zh) 2008-09-03
ES2262567T3 (es) 2006-12-01
HUP0303600A3 (en) 2011-11-28
FR09C0041I1 (enExample) 2009-10-30
MXPA03008467A (es) 2003-12-08
EP1373300A2 (en) 2004-01-02
CN101332292B (zh) 2012-06-20
SK287539B6 (sk) 2011-01-04
NO20033629L (no) 2003-08-15
JP4955906B2 (ja) 2012-06-20
KR20040004369A (ko) 2004-01-13
CN101332292A (zh) 2008-12-31
EP1243262A1 (en) 2002-09-25
DK1243262T3 (da) 2006-10-02
CY2009013I1 (el) 2012-01-25
WO2002074784A3 (en) 2002-11-21
US6803481B2 (en) 2004-10-12
SI1373300T1 (sl) 2009-10-31
BR0205823A (pt) 2003-10-21
SK12832003A3 (sk) 2004-02-03
AU2002257681A2 (en) 2002-10-03
US8053476B2 (en) 2011-11-08
CY1105533T1 (el) 2010-07-28
CZ20032763A3 (cs) 2004-01-14
NO20033629D0 (no) 2003-08-15
KR100773100B1 (ko) 2007-11-02
ZA200300858B (en) 2003-07-09
JP2004524340A (ja) 2004-08-12
NZ523865A (en) 2004-12-24
DE122009000053I1 (de) 2010-05-27
AU2002257681C1 (en) 2008-02-21
ATE431833T1 (de) 2009-06-15
ES2326627T3 (es) 2009-10-16
CY1109308T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
NL300399I1 (en) Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
EA200300933A1 (ru) Новое применение соединения из класса пептидов для лечения аллодинии или других различных типов хронической или фантомной боли
WO2002085342A3 (en) Use of nsaids for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
DE60105419D1 (de) Serinprotease-inhibitoren
EA200400410A1 (ru) Комбинация нспвлс и ингибитора pde-4
CY1112555T1 (el) Διεργασια χημικης συζευξης με ενα παραγωγο φαινυλ βορονικου οξεος
BRPI0414622A (pt) métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias
BR0010426A (pt) Processo para o tratamento de uma carga de alimentação composta de alfa olefinas funcionalizadas e olefinas internas funcionalizadas
WO2003005956A3 (en) A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity
EP1932824A4 (en) METHOD FOR SYNTHESIS OF A KETOIC ACID OR AMINO ACID BY HYDRATISING AN ACETYLENE COMPOUND
FR2841241B1 (fr) Procede d'alkylation de composes aromatiques par le methane
TH66369A (th) เบนซิมิดาโซลที่มีประโยชน์ในการบำบัดความบกพร่องทางเพศ
NO974537D0 (no) Plateaggregeringsinhibitorer inneholdende C-terminale aminergiske sidekjedeaminosyrerester
TH83329A (th) สารผสมที่เป็นประโยชน์ในฐานะสารยับยั้งของ gsk-3